Particle Therapy Market Report 2025

The particle therapy market size has grown rapidly in recent years. It will grow from $1.23 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to clinical research and studies, increased cancer incidence, government support and funding, industry collaboration, and improvements in treatment planning.

The particle therapy market size is expected to see rapid growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing healthcare expenditure, emerging applications beyond cancer, a rise in the geriatric population, healthcare infrastructure development, AI and data analytics integration. Major trends in the forecast period include advancements in particle accelerator technology, hypofractionation techniques, proton and carbon ion combination therapy, improved patient comfort, and biology-driven treatment protocols.

The increasing prevalence of cancer is anticipated to drive the growth of the particle therapy market in the future. Cancer is a complex and varied group of diseases marked by the abnormal growth and multiplication of cells in the body. Particle therapy effectively treats cancer through precise radiation delivery, utilizing positively charged particles (protons) that are accelerated to high speeds and focused on the tumor. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency, reported that nearly 20 million new cancer cases were recorded in 2022, resulting in almost 10 million deaths. Projections based on demographic trends indicate that the annual incidence of new cancer cases could reach 35 million by 2050, representing a 77% increase from the 2022 figures. Therefore, the rising prevalence of cancer is a key factor driving the growth of the particle therapy market.

The increasing aging population is projected to contribute to the growth of the particle therapy market in the coming years. An aging population refers to a demographic shift characterized by a growing proportion of elderly individuals within a society. Particle therapy is particularly beneficial for the geriatric population as it offers a precise and targeted approach to cancer treatment, minimizing damage to surrounding healthy tissues and reducing the risk of long-term side effects, thereby enhancing the quality of life for older patients receiving cancer therapy. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, estimated that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. This age group's share of the total population is also expected to grow from 17% to 23% during the same period. Thus, the aging population is a significant driver of the particle therapy market.

Advanced particle therapy platforms are becoming a significant trend in the particle therapy market. Key players in this field are focusing on developing innovative particle therapy solutions to maintain their competitive edge. For example, in July 2023, RaySearch Laboratories, a Sweden-based medical technology firm, introduced RayStation 2023B. This comprehensive oncology treatment planning system incorporates several groundbreaking advancements in particle therapy, including support for discrete proton arcs and robust optimization based on linear energy transfer (LET). LET optimization aims to minimize potential side effects by reducing LET in at-risk organs while directing high LET particles to tumors for better tumor control. Additionally, discrete proton arc optimization allows for a wider range of beam angles, resulting in more conformal dose distributions and less exposure for sensitive organs. The software also offers easy conversion to standard pencil-beam scanning plans, automatic field-in-field planning for photon treatments, point-based optimization for brachytherapy, and improved data loading speeds.

Key companies in the particle therapy market are intensifying their efforts to develop innovative therapies, with a particular focus on proton therapy solutions, to gain a competitive advantage. Proton therapy technology, a sophisticated form of cancer treatment utilizing protons and positively charged particles, delivers precise and targeted radiation to cancer cells. For instance, in April 2023, P-Cure, an Israel-based high-med-tech company, obtained clearance from the United States Food and Drug Administration (USFDA) for its Adaptive Proton Therapy Solution, allowing sales in the USA. This affordable proton therapy technology is designed for targeted cancer treatment with significantly reduced treatment-related side effects. P-Cure's innovative upright solution, the world's first FDA-approved methodology for patient positioning, enables seated treatment, enhancing both patient comfort and clinical outcomes.

In May 2022, Brainlab AG, a Germany-based medical technology company, acquired a majority stake in medPhoton GmbH for an undisclosed amount. This strategic acquisition aims to expand Brainlab's intraoperative imaging portfolio, drive business growth, bolster product development, and accelerate innovation in the critical field of medical technology. medPhoton GmbH, an Austria-based medical equipment manufacturing company, specializes in providing particle therapy devices and services.

Major companies operating in the particle therapy market include Hitachi Ltd., Mitsubishi Electric Corporation, Siemens Healthineers AG, Koninklijke Philips N.V, GE Healthcare, Sumitomo Heavy Industries Ltd., Varian Medical Systems Inc., Elekta AB, Shinva Medical Instrument Co. Ltd., Toshiba Medical Systems Corporation, Brainlab AG, Accuray Incorporated, IBA Worldwide, Mevion Medical Systems Inc., Avante Health Solutions, Provision Healthcare LLC, ViewRay, Panacea Biotec Ltd., PTW Freiburg GmbH., ProNova Solutions LLC, Optivus Proton Therapy Inc., Xstrahl Inc., Protom International Inc., Danfysik AS, SAH Global LLC, Advanced Oncotherapy plc, Particle Therapy Co-Operative Group, Best Particle Therapy Inc.

North America was the largest region in the particle therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the particle therapy market report during the forecast period. The regions covered in the particle therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the particle therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Particle therapy is an advanced cancer treatment that employs charged particles, such as protons or heavier ions, to administer radiation therapy directly to cancerous tumors. This method primarily targets energetic ionizing particles at the tumor location, aiming to improve treatment outcomes for patients with various types of tumors, particularly those that are difficult to treat using conventional radiation therapy.

Two primary types of therapies fall under the umbrella of particle therapy, proton therapy and heavy ion therapy. Proton therapy is a specialized form of radiation therapy employed in cancer treatment. It encompasses both single-room systems and multi-room systems, providing versatility in its application. Proton therapy is utilized for the treatment of various cancers, including but not limited to pediatric cancer, prostate cancer, lung cancer, breast cancer, and cancers affecting the brain and spinal cord. The primary end users of particle therapy are hospitals, academic institutions, and research centers. Particle therapy offers a targeted and precise approach to cancer treatment, minimizing damage to surrounding healthy tissues and enhancing the therapeutic effectiveness of radiation.

The particle therapy market research report is one of a series of new reports that provides particle therapy market statistics, including particle therapy industry global market size, regional shares, competitors with a particle therapy market share, detailed particle therapy market segments, market trends and opportunities, and any further data you may need to thrive in the particle therapy industry. This particle therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The particle therapy market includes of revenues earned by entities by providing particle therapy services such as treatment planning, particle beam delivery, imaging and simulation, treatment sessions, patient monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.